Home
Storia in 1 fonti
Kiran Mazumdar-Shaw warns against long-term GLP-1 use, urges caution over weight-loss drugs, says 'for those who are not diabetic or clinically obese...'
Nithin Kamath questions India's slow adoption of affordable GLP-1 weight-loss drugs, despite rising obesity. He points to challenges like long-term adherence and physician conservatism. Biocon's Kiran Mazumdar-Shaw weighed in and urged caution, emphasizing diet and exercise as primary options for non-diabetic, non-obese individuals, citing potential long-term side effects of these metabolic-altering medications.
Raccontata da
economictimes.indiatimes.com
Timeline cronologica
- ·
India's GLP-1 boom slows amid price war, weak retention
Initial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-expected prescriptions and patient…
- ·
'Cheaper than a gym, but still not selling': Nithin Kamath on why Indians aren't embracing popular weight-loss drugs
Despite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Nithin Kamath highlights patient retention challenges with weekly injections and conservative…
- ·
Kiran Mazumdar-Shaw warns against long-term GLP-1 use, urges caution over weight-loss drugs, says 'for those who are not diabetic or…
Nithin Kamath questions India's slow adoption of affordable GLP-1 weight-loss drugs, despite rising obesity. He points to challenges like long-term adherence and physician…